 Connection
Jeffrey Swigris to Pyridones
This is a "connection" page, showing publications Jeffrey Swigris has written about Pyridones.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.798 |
|
|
|
-
Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016 09; 48(3):843-51.
Score: 0.466
-
Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, Swigris JJ. Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2021 02; 57(2).
Score: 0.159
-
Guler SA, Lindell KO, Swigris J, Ryerson CJ. Medications for Idiopathic Pulmonary Fibrosis: IPF Part 2. Am J Respir Crit Care Med. 2021 02 01; 203(3):P7-P8.
Score: 0.159
-
Antoniou K, Kamekis A, Symvoulakis EK, Kokosi M, Swigris JJ. Burden of idiopathic pulmonary fibrosis on patients' emotional well being and quality of life: a literature review. Curr Opin Pulm Med. 2020 09; 26(5):457-463.
Score: 0.155
-
Maher TM, Swigris JJ, Kreuter M, Wijsenbeek M, Cassidy N, Ireland L, Axmann J, Nathan SD. Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. Respiration. 2018; 96(6):514-524.
Score: 0.134
-
Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 09 15; 196(6):756-761.
Score: 0.126
-
Nathan SD, Albera C, Bradford WZ, Costabel U, Glaspole I, Glassberg MK, Kardatzke DR, Daigl M, Kirchgaessler KU, Lancaster LH, Lederer DJ, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. Lancet Respir Med. 2017 01; 5(1):33-41.
Score: 0.119
-
Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 05; 71(5):429-35.
Score: 0.113
-
Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan; 47(1):243-53.
Score: 0.111
-
Lederer DJ, Bradford WZ, Fagan EA, Glaspole I, Glassberg MK, Glasscock KF, Kardatzke D, King TE, Lancaster LH, Nathan SD, Pereira CA, Sahn SA, Swigris JJ, Noble PW. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest. 2015 Jul; 148(1):196-201.
Score: 0.108
-
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.100
-
Fern?ndez P?rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, Solomon JJ, Mohning MP, Groshong SD, Fier K. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023 11; 78(11):1097-1104.
Score: 0.046
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|